

1 **Supplementary Materials**

2

3 **Abbreviations**

4 BDNF= brain-derived growth factor, CAMK2N1= calcium/calmodulin-dependent protein
5 kinase II inhibitor 1, CBF= cerebral blood flow, DEGs= differentially expressed genes, DC=
6 duty cycle, EMG= electromyography, GO= gene ontology, HMGB1= high mobility group
7 protein B1, IS= ischemic stroke, LIFUS= low-intensity focused ultrasound stimulation,
8 MCAO= middle cerebral artery occlusion, PRF= pulse repetition frequency, SD= sonication
9 duration, UMAP= uniform manifold approximation and projection, US= ultrasound
10 stimulation, VEGF= vascular endothelial growth factor

11

12 **Methods**

13 **Group and use of mice**

14 In sham-related groups, we used n = 6 per group for laser speckle, n = 4 per group for Golgi
15 staining and western blot, and n = 3 per group for FISH, cresyl violet-staining,
16 immunostaining, fiber photometry, EMG, and neurobehavioral, what's more, we used n = 8
17 per group to be 1 sample for scRNA seq, total is 42, which was used to show that the
18 intensity, frequency, and duration of ultrasound used in this research did not produce
19 significant trends in normal mice. HMGB1 inhibition and CAMK2N1 overexpression in
20 normal mice mainly to show that gene manipulations had no effect on sham mice.

21 In stroke related groups, we used about n = 10-12 per group for laser speckle and
22 neurobehavioral, n = 7 for cresyl violet-staining, n = 4 per group for immunostaining, Golgi
23 staining and western blot, and n = 3 per group for FISH, fiber photometry, EMG and iTRAQ
24 proteomics, what's more, we used n = 8 per group to be 1 sample for scRNA seq. At the
25 same time, to maximize the use of mice, we performed laser speckle, fiber photometry or
26 electromyography on days 7 and 13, or neurobehavioral on days 7 and days 14, then
27 sacrificed the mice, which could be used for immunostaining, Golgi staining and Western
28 blot. Total is 78. Based on the above, we used 120 mice (pre-experiments and died mice are
29 not included) to get feasible results and corresponding significance in the experiments.

30 **A mouse model of transient middle cerebral artery occlusion (MCAO)**

31 Animal studies were approved by the Institutional Animal Care and Use Committee (IACUC)
32 of Shanghai Jiao Tong University, Shanghai, China. They were conducted in accordance with
33 the national laws for the use of animals in research and followed the ARRIVE (Animal
34 Research: Reporting of *in vivo* Experiments) guidelines. MCAO was performed as described
35 following. Briefly, adult mice were anesthetized with 1%-1.5% isoflurane and 30%/ 70%
36 oxygen/nitrous oxide. Body temperature was maintained at 37.0±0.5°C using a heating pad.
37 The common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery
38 (ECA) were separated, and a 6-0 suture (Covidien, Mansfield, MA) coated with silicon

39 (Heraeus Kulzer, Germany) was inserted from ECA, followed by ICA, until the opening of
40 MCA. The success of occlusion was determined by monitoring the decrease in surface CBF
41 to the 10% of baseline CBF using a laser Doppler flowmetry (Moor Instruments, Devon,
42 UK). The filament was then removed 90 min after MCAO to allow blood flow restoration.

43 **Ultrasound stimulation system**

44 A focused ultrasound transducer (Ultrasound Neurostimulation System, Shenzhen Institute of
45 Advanced Technology, Chinese Academy of Sciences, Shenzhen, China) with center
46 frequency (f) 500 kHz, PRF 1 kHz, SD 300 ms, and DC 50% was used across the ultrasound
47 stimulation experiment. The design of ultrasound stimulation parameters showed in the
48 supplementary materials and the focused ultrasound transducer was placed right above the
49 ipsilateral hemisphere of brain.

50 **Laser sparkle imaging examination**

51 Mice were anesthetized with isoflurane and fixed on the stereotaxic apparatus. Seven days
52 and 13 days after MCAO, CBF was measured before and after LIFUS by a laser speckle
53 imaging machine (RWD, Shenzhen, China). The relevant parameters were as followed, the
54 exposure time was 1 ms, the shooting time was 5 sec, 2 frames per sec, the magnification was
55 3 times, and the laser intensity was 110 mW. Two data processing methods were used. For
56 the immediate response of ipsilateral hemisphere after ultrasound stimulation following 7 and
57 13 days of MCAO, CBF of ROI was calculated as $(CBF_{End}-CBF_{Start})/CBF_{Start}$ %. Absolute
58 CBF detected before ultrasound at day 7 and day 13, which was considered as the endpoint
59 CBF of ipsilateral hemisphere. Absolute value was changed to ratio of ipsilateral/contralateral
60 CBF in **Fig. 4** to avoid the influence of external factors on laser speckle value, and
61 contralateral CBF was as a control.

62 **Atrophy volume assessment by cresyl violet staining**

63 A series of 20 μ m in thickness and 200 μ m in interval brain cryosections from anterior
64 commissure to lateral ventricle were collected. The sections were stained with 0.1% cresyl
65 violet solution (Sigma, St Louis, MO), and then the atrophied areas were measured by
66 subtracting the stained area in the ipsilateral hemisphere area from the contralateral
67 hemisphere using Image *J* (NIH, Bethesda, MD) software. The brain atrophy volume was
68 calculated with the following formula: $V = \sum h/3 * [\Delta S_n + (\Delta S_n * \Delta S_{n+1})^{1/2} + \Delta S_{n+1}]$, in which
69 V represents volume, h represents the distance between the two adjacent brain sections, ΔS_n
70 and ΔS_{n+1} represent the area differences between the two adjacent sections. Areas were then
71 integrated to obtain the total atrophy volume. Atrophy size assessment was performed by a
72 blinded investigator.

73 **iTRAQ proteomics analysis**

74 Proteins were isolated from the perifocal regions of the ischemic stroke (IS) and IS
75 ultrasound stimulation (US) groups, at least 3 independent samples for each group. Proteins
76 were extracted then the concentrations were measured by the BCA assay. Samples were
77 analyzed by SDS-PAGE. Trypsin was used for enzymolysis to get peptides that were labeled

78 with iTRAQ 8PLEX (4381663, ABSCIEX). The equally mixed labeled peptides were
79 separated by RPLC on an 1100 HPLC System (Agilent) with an Agilent Zorbax Extend RP
80 column (5 μ m, 150 mm X 2.1 mm). Subsequently, Liquid chromatography tandem-mass
81 spectrometry (LC-MS/MS) was performed for the identification and quantification of
82 proteins. Samples were loaded by a capillary trap column (100 μ m X 2 cm, RP-C18, Thermo
83 Fisher, Waltham, MA) and then separated by a capillary analytical column (15 cm X 75 μ m,
84 RP-C18, Thermo Fisher) on an EASY-nLC™ 1200 system (Thermo Fisher). All analyses
85 were performed by a Q-Exactive mass spectrometer equipped with a Nanospray Flex source
86 (Thermo Fisher). Tissue processing and data acquisition were performed by Oebiotech
87 (Oebiotech, Shanghai, China). A $p < 0.05$ and $|\log 2\text{-fold change}| > 0.58$ was set as the
88 threshold for significantly differential expression.

89 **Single-cell RNA sequencing**

90 Ipsilateral target tissues from IS, IS US, sham or US, mice ($n = 8/\text{group}$) were rapidly and
91 carefully collected and dissociated using adult brain dissociation kit from Miltenyi Biotec
92 (Bergisch Gladbach, Germany). Single-cell gel beads in emulsions (GEMs) were generated
93 by loading single-cell suspensions onto a Chromium Single-Cell Controller Instrument (10X
94 Genomics). Approximately 12,000 cells were added to each channel. Next, reverse
95 transcription reactions were engaged to generate barcoded full-length cDNA, and cDNA
96 clean-up was performed with DynaBeads Myone Silane Beads (Thermo Fisher). Then cDNA
97 was amplified by PCR and the amplified cDNA was fragmented, end-repaired, A-tailed, and
98 ligated to an index adaptor, and then the library was amplified. Every library was sequenced
99 on a HiSeq X Ten platform (Illumina), and 150 bp paired-end reads were generated. Tissue
100 processing and data acquisition were then performed (Oebiotech, Shanghai, China).

101 **scRNA seq data preprocessing and analysis**

102 To remove the batch effects in single-cell RNA-sequencing data, the mutual nearest
103 neighbors (MNN) was performed with the R package batchelor. To remove low-quality cells
104 and likely multiple captures, which was a major concern in microdroplet-based experiments,
105 we applied a criterion to filter out cells with UMI/gene numbers out of the limit of mean
106 value ± 2 fold of standard deviation assuming a Gaussian distribution of each cells' UMI/gene
107 numbers. Following visual inspection of the distribution of cells by the fraction of
108 mitochondrial genes expressed, we further discarded low-quality cells where 10% of counts
109 belonged to mitochondrial genes and $>5\%$ of the counts belonged to hemoglobin genes.
110 Library size normalization was performed in the Seurat on the filtered matrix to obtain the
111 normalized count. Top variable genes across single cells were identified using Macosko's
112 method. To remove the batch effects in single-cell RNA sequencing data, the mutual nearest
113 neighbors (MNN) presented was performed with the R package batchelor. Graph-based
114 clustering was performed to cluster cells according to their gene expression profiles using the
115 FindClusters function. Cells were visualized using a 2D Uniform Manifold Approximation
116 and Projection (UMAP) algorithm with the Run UMAP function. FindAllMarkers function
117 was used to identify marker genes of each cluster and identified positive markers for a given
118 cluster compared with all other cells. Then we used the MouseRNAseqData package in

119 SingleR, a computational method for unbiased cell type recognition of scRNA-seq to infer
120 the cell of origin of each of the single cells independently and identify cell types.
121 Differentially expressed genes (DEGs) were identified using the Seurat package. A $p < 0.05$
122 and $|\log 2\text{-fold change}| > 0.58$ was set as the threshold for significantly differential
123 expression. GO enrichment pathway enrichment analysis of DEGs were respectively
124 performed using R based on the hypergeometric distribution.

125 **Viral vector production and injection**

126 Adeno-associated virus (AAV-PHP.eB) was packaged commercially (OBiO Technology
127 Corp., Ltd., Shanghai, China). After purification, the viral titer was determined by real-time
128 PCR. A total volume of 100 μl of PBS containing 3×10^{12} viral particles was injected by tail
129 vein injection two weeks before MCAO. U6 and GfaABC1D promoter-driven shRNA
130 perturbations were established in pAAV-U6/GfaABC1D-shRNA v2.0-CMV-WPRE vector,
131 respectively. HMGB1 shRNA was designed based on the CDS sequence confirmed on Sigma
132 (TRCN0000365912), which efficiently knocked down 95% HMGB1 expression in B16-F0
133 cells. Positive clones were sent for sequencing and plasmid extraction was followed then
134 HMGB1 primer was confirmed as forward primer 5'-TGACAAGGCTCGTTATGAAAG-3'
135 and reverse primer 5'-CTTTCATAACGAGCCTTGTC-3'. Then sequence subcloned into
136 the new pAAV scramble to be pAAV-U6-sh (HMGB1)-CMV-WPRE and pAAV-
137 GfaABC1D-sh (HMGB1)-CMV-WPRE. Similarly, CAG and GfaABC1D promoter-driven
138 Camk2N1 overexpression systems were established in the pAAV-CAG-P2A-3xFLAG-
139 WPRE vector and pAAV-GfaABC1D-P2A-3xFLAG-WPRE vector, respectively.
140 CAMK2N1 was designed by its CDS, primer was confirmed as forward primer 5'-
141 CATGGTCCTGCTGGAGTTCGTG-3' and reverse primer 5'-
142 CATAGCGTAAAAGGAGCAACA-3'. Targeted gene was designed based on the CDS
143 sequence, then sequence subcloned into the new pAAV scramble to be pAAV-CAG-P2A-
144 CAMK2N1-3xFLAG-WPRE and pAAV-GfaABC1D-P2A-CAMK2N1-3xFLAG-WPRE,
145 correspondingly. In addition, we used gf to indicate GFAP in the figures.

146 **Brain tissue collection**

147 For immunostaining and Western blotting analysis, mice were perfused intracardially with
148 cold sterile 1x PBS followed at 14 days of MCAO mice. The whole brain was immediately
149 frozen in liquid nitrogen (-20°C , 10 min) then transferred to a -80°C deepfreeze.
150 Cryosection (20 μm in thickness) from anterior commissure to hippocampus were cut and
151 collected using a cryostat. Immunostaining was carried out by sampling one section per 200
152 mm, and 4 to 5 sections were collected effectively span the entire injured region of each
153 mouse. Similarly, one section per 200 mm was collected and stored at -20°C for qPCR, eight
154 sections per 200 mm was collected for Western blotting analysis. We collected 10 sections
155 from 200 mm in thickness to make samples for mRNA, protein or immunostaining were all
156 from the same mice and results could be more solid from molecular level to histological
157 level. Then cold TRIzol reagent was added into samples for qPCR, precooled protein lysis
158 buffer (RIPA with protease cocktail inhibitor, and phosphatase inhibitor) was used to extract
159 protein. For sampling of iTRAQ proteomics and scRNA seq, MCAO mice were perfused

160 intracardially with cold sterile 1X PBS after LIFUS. The brain was rapidly placed in a cold
161 mouse brain matrix. The brain was cut into a 2 mm-thick section before and behind the center
162 of Willis Circle. A 2 mm punch was used to separate the target region in the ipsilateral
163 penumbra.

164 **Immunostaining**

165 Brain sections were fixed by 4% paraformaldehyde (PFA, Sinopharm Chemical Reagent,
166 China) for 10 min, after rinsed, the sections were incubated with 0.3% TritonX-100 (Sigma,
167 St Louis, MO) for 10 min and blocked with 5% bovine serum albumin (BSA, GBICO, MA).
168 Brain sections were then incubated with goat-anti CD31 (1:200, AF3628, R&D, Minneapolis,
169 MN), rabbit-anti Ki67 (1:200, ab15580, Abcam, Cambridge, England) at 4°C overnight.
170 After rinsing with PBS for 3 times, brain sections were incubated with the secondary
171 antibodies: Alexa fluor 488-conjugated donkey anti-rabbit secondary antibody (1:400,
172 A21206, Invitrogen, Carlsbad, CA) and Alexa fluor 555-conjugated donkey anti-goat
173 secondary antibody (1:400, A21432, Invitrogen) for 1 hour at 37°C. For mice injected with
174 lectin DyLight 594 (*Lycopersicon esculentum* (Tomato), L32471, Invitrogen), sections were
175 co-immunostaining with Ki67 and proceeded to subsequent staining steps. Images were
176 acquired using a confocal microscope (TCS SP5, Leica).

177 **Western blotting analysis**

178 Equal amounts of protein (20 µg) were loaded onto 10% (W/V) sodium dodecyl sulfate-
179 polyacrylamide gel electrophoresis and electrophoresed. The proteins were transferred onto
180 PVDF Transfer Membrane, (0.45 µm, RIPA, Millipore, Burlington, Mass) and incubated
181 with the primary antibodies (**Table S4**) at 4°C overnight. The membrane was washed in
182 1XTBST buffer and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit or
183 anti-mice IgG (1:5000, Invitrogen) for 1 hour at RT, and then reacted with an enhanced
184 chemiluminescence substrate (Meilunbio, Shanghai, China). Bright-field image and
185 chemiluminescent blots were merged using Tanon GIS software (www.Bio-tanon.com.cn).
186 The result of chemiluminescence was semi-quantified using the ImageJ software (NIH,
187 Bethesda, MD).

188 **Fluorescence *in situ* hybridization**

189 *In situ* hybridization was performed using one biotin-labeled riboprobe for HMGB1 (5'-
190 GCTTTCTTCTCATAGGGCTGCTTGTCATC -3') and 2 mix biotin-labeled riboprobes
191 CAMK2N1 (5'- CCGTAGGGCAGCACCTCCGACAT-3' and 5'-
192 GGCTCAGCTTCTCGTCGCCGTA-3'). Probes were synthesized and subsequent
193 fluorescence *in situ* hybridization was performed by Gene Pharma (Shanghai, China). Brain
194 cryosections (30 µm) were reactivated in citrate buffer (RT, 15 min), treated with proteinase
195 K (37°C, 20 min) followed by blocked (37°C, 30 min), denatured (78°C, 2 min), dehydrated
196 using graded ethanol (RT, 8 min) and then hybridized with probe working solution (biotin-
197 probe: SA-Cy3: PBS = 8:1:1) in hybridization buffer overnight at 37°C. Hybridized sections
198 were washed with 0.2 x saline-sodium citrate (SSC) buffer for 15 min (wash I), with 2 x
199 SSC at 60°C for 30 min (wash II), and washed at 37°C for 30 min (wash III). For

200 immunostaining, sections were incubated with anti-GFAP (1:100, ab53554, Abcam) primary
201 antibody overnight at 4°C. After being washed with PBS, slices were incubated with a second
202 antibody (1:400, A11055, Invitrogen). Images were visualized under a confocal microscope.

203 **Golgi-Cox staining**

204 Golgi-Cox staining were strictly followed by the manufacturer's instructions (FD Rapid
205 GolgiStain™ Kit, MD). Brains were quickly removed and rinsed, and then immersed in a 1:1
206 mixture of solutions A and B (containing mercuric chloride, potassium dichromate and
207 potassium chromate) for 2 weeks at RT in dark. Brains were then transferred to solution C
208 and kept in the dark for 4 days. Solution C was replaced after the first 24 hours. Brains were
209 rapidly frozen in isopentane and kept at -80°C until sectioning. Cryosectioning was
210 performed on a sliding microtome (Leica). Coronal sections of 100 µm thickness were cut
211 and transferred to microscope slides (Lab Scientific) onto small drops of solution C and
212 allowed to dry at RT overnight. Serial sections were stained with a mixture of D and E
213 solutions for 10 min, then dehydrated in a series of graded ethanol, cleared in xylene, and
214 cover slipped with neutral resin. Single-plane images were taken under a light field using a
215 confocal microscope (Leica).

216 **Neurobehavioral tests**

217 Neurobehavioral tests were performed before and 1, 3, 7, and 14 days after MCAO by an
218 investigator blinded to the experimental design and treatment.

219 **Modified neurologic severity score (mNSS)**

220 mNSS included a combination of motor, reflex, and balance tests. Severity scores ranged
221 from 0 to 14, with 0 being normal and higher scores indicating more severe damage.

222 **Tail suspension test**

223 The tail suspension test was to raise the tail of a mouse to observe its deviation from the
224 vertical midline. Each observation was repeated 20 times at 1 min interval, and the shift to the
225 right/total was recorded.

226 **Grid-walking test**

227 The elevated grid walking apparatus was manufactured using wire mesh with a grid area of
228 32 cm/20 cm/50 cm (length/width/height). Each mouse was individually placed on the grid
229 and allowed to walk freely for 5 min. A step was considered a stepping error (foot fault) if it
230 did not provide support and the foot went through the grid hole. The total number of foot
231 failures in right limb, as well as the total number of steps taken were counted. The ratio of
232 foot faults was calculated as (contralateral faults/ total steps) *100%.

233 **Rotarod test**

234 The Rotarod test evaluates motor coordination function and balance. Mice were trained for 3
235 consecutive days before surgery. The Rotarod was accelerated from 5 to 40 rpm. for 300 sec
236 as preoperative baseline. Following surgery, three trials were performed for each mouse.

237 Motor performance was assessed and the latency before falling off the accelerating rotating
238 rod was recorded with a maximum of 300 sec.

239 **Electromyogram recording**

240 We recorded signals from electromyography using a commercialized system RZ2 BioAmp
241 Processor (Tucker-Davis Technologies, TDT, Alachua County, FL). Connecting the RZ2
242 Interface to PC and a PZ PreAmplifier to amplify signals, these electrical signals were
243 translated into numerical values automatically. We implanted 5 fibers together in one mouse,
244 two fibers implanted in the left hind limb, one of them connected to the positive pole, another
245 connected to the negative pole, both two were in the same coordinates. Similarly, two fibers
246 implanted in the right hind limb were connected in the same way, and the last fiber was
247 connected to a backside grounding pole. Bandpass filtered (1017 Hz) amplitude of the
248 electromyogram was collected automatically and visualized and completed the digital
249 transformation by Synapse Software, which means after that data could be exported,
250 processed and quantified by using custom MATLAB (MathWorks) scripts. Then
251 electromyogram data were recorded continuously (300 sec were the total record duration, the
252 former 60 sec were for baseline, the middle 240 sec were for ultrasound stimulation, and the
253 last 60 sec were for post-record) in overall 5 min. For the statistical charts, average EMG
254 amplitude values were calculated as (EMG duration - EMG baseline)/EMG baseline. EMG
255 baseline was the mean of the amplitude signals from 1 sec to 60 sec. The heat map was
256 plotted using a self-developed R program to display the variance of amplitude in 3 individual
257 mice from each group.

258 **Fiber photometry recording**

259 We used a commercialized system (R810 dual-color multi-channel fiber photometry
260 recording system, RWD) to detected calcium signals from neurons with LIFUS. Two weeks
261 before MCAO, a total volume of 200 nl of PBS containing 5×10^9 pAAV-CMV-GCaMP6s-
262 P2A-nls-dTomato (AAV2/9) viral particles were injected stereotactically at a rate of 50
263 nl/min at 1.7 mm lateral to the bregma and 3.5 mm under the dura using a micro-infusion
264 pump (WPI, city, FL). The needle was left in place for 5 min to avoid reflux. After
265 withdrawal to 3.4 mm ventral to the bregma, repeat the steps above and wait for 10 min to
266 avoid reflux for the second time. The scalp was then sutured. Then mice were still
267 anesthetized using isoflurane and fixed on a stereotaxic frame, optical fibers (200 μ m O.D.,
268 0.22 NA, RWD) were implanted into the exact place of 200 μ m above viral vector injection
269 coordinates, 3.5 mm under the dura is the exact coordinate to allow for optogenetic
270 manipulation of neuron calcium florescence detect. The fiber was secured to the skull with
271 bone screws and dental cement for every mouse. Mice were allowed to recover for 2 weeks
272 after implantation, then performed MCAO. Mice were habituated for 10 min after connection
273 to a laser source. A laser at wavelengths of 470 nm (blue) was applied and controlled with an
274 intelligent optogenetic system to excite the GCaMP6s fluorescent protein, laser at
275 wavelengths of 410 nm was used as the reference, which effectively removed the motion
276 artifact interference and obtained the real fluorescence signal in GCaMP6s-expressing mice.

277 **Fiber photometry record analysis**

278 The normalized DF/F values and traces were visualized by the R810 dual-color multi-channel
279 optical fiber recording system itself and it can export data to be further processed using
280 custom MATLAB (MathWorks) scripts to draw averaged Ca²⁺ traces. For the statistical
281 charts, average DF/F (%) values were calculated as (F_{duration}-F_{baseline})/F_{baseline}. Fiber
282 photometry was recorded (300 sec was the total record duration, the former 60 sec was for
283 baseline, the middle 240 sec was for ultrasound stimulation, and the last 60 sec for post-
284 record) in overall 5 min, F_{baseline} was the mean of the GCaMP6m signals from 1 sec to 60
285 sec, and F_{duration} was the mean of GCaMP6m signals for 5 min record displayed on the
286 statistical charts. The heatmap was plotted using a self-developed R program to display the
287 variance of average DF/F (%) in 3 individual mice from each group. The GCaMP6s
288 fluorescence was bandpass filtered automatically and fluorescence intensity and change were
289 converted to a digital signal to be recorded and quantified automatically by fiber photometry
290 recording system (RWD).

291 **Image acquirement**


292 Quantitative analysis of the acquired images was performed using LAS AF Lite for
293 quantification of cell numbers and Image J software for quantification of fluorescence
294 intensity. Four images of the penumbra surrounding the injury core in the ipsilateral
295 hemisphere were taken under a confocal microscope (experimental protocol). For co-
296 localization assays, the number of positive cells was counted in LAS AF Lite software. For
297 dendritic spine quantification, representative brain coronal sections (100 μm thick) of
298 ipsilateral perifocal region were imaged under confocal microscope, x 20 and x 120 images
299 were taken at a single panel.

300 **Statistical analysis**

301 Data analysis was performed with IBM SPSS Statistics 24 at a confidence of 95%, and
302 figures were generated from GraphPad Prism 9. All values were presented as mean ± SD.
303 Animals used (N) was indicated in the figure legends. Normality of continuous variables was
304 assessed by the Kolmogorov-Smirnov test if $n \geq 30$ and the Shapiro-Wilk test if $n < 30$. To
305 assess the difference between two independent groups, an unpaired two-tailed test was used
306 for normally distributed variables. One-way or two-way analysis of variance followed by
307 Dunnett's or Tukey's multiple comparisons were used for more than two groups. Results
308 were presented as means ±SD. A $p < 0.05$ was considered statistically significant.

309 **Data and materials availability**


310 The datasets produced in this study are available in the following databases: scRNA-seq:
311 BioProject accession is PRJNA882071
312 (<https://submit.ncbi.nlm.nih.gov/subs/bioproject/SUB12080901/overview>), BioSample
313 accession are SAMN30928884 and SAMN30928936
314 (<https://www.ncbi.nlm.nih.gov/biosample/30928936>). Proteomics: iProX dataset identifier
315 PXD036927, the corresponding password is: A6IZ.
316 (<https://www.iprox.cn/page/PSV023.html?url=1681800664925SwUt>).
317

318 **Supplementary Figures**

319

320 **Supplementary Figure 1. Experimental scheme.** Scheme of experimental timepoints
321 included virus injection, optical fibers implantation, ultrasound stimulation, laser speckle,
322 EMG, fiber photometry records, neurobehavioral tests and a series of immunohistochemistry
323 after animal sacrifice.

324



325

326 **Supplementary Figure 2. LIFUS promoted angiogenesis and neurobehavioral outcomes**327 **in MCAO mice. (A)** Laser speckle imaging showed immediate change of CBF when 22,328 101, 201 mW/cm²-sound pressure was tested on the MCAO mouse brain with 1, 3, 5 min329 respectively, (n = 4 mice/group). **(B-D)** mNSS records for neurobehavioral outcomes in each330 group at 14 days of MCAO, (n = 4 mice/group). **(E)** Representative laser speckle images of

331 CBF of ROI after immediate, 7 days and 13 days of MCAO in the mouse brain. The start row

332 showed CBF absolute value at 7 days and 13 days after MCAO respectively. The end row

333 showed immediate CBF recording followed by ultrasound at 7 days and 13 days respectively.


334 **(F)** Semi-quantification of the CBF, (n = 6 mice/group). **(G)** qPCR results for mRNA level of

335 VEGF, BDNF and eNOS in ipsilateral hemisphere of the mouse brain, (n = 4 mice/group).

336 US1, 2 = mice treated with different dose of ultrasound. IS = ischemic stroke mice, IS US =

337 ischemic stroke mice treated with US. Data are mean ± SD.


338



339

340 **Supplementary Figure 3. Differential expressed genes and expression profiles in iTRAQ**
 341 **proteomics and scRNA-seq analysis. (A) Volcano Plot demonstrated fold change of protein**
 342 **level in IS US group compared to the IS group. (B) Dot plot of marker genes for different cell**

343 clusters by scRNA seq. **(C)** Expression profiles of three subclusters in astrocytes by grouped
344 groups were shown and colored based on gene expression patterns. **(D)** Secondary profile of
345 3 subclusters in astrocytes. **(E)** Heatmap showed differential expressed genes in three
346 subclusters of astrocytes. **(F)** Violin plots represented the expression distributions of HMGB1
347 and CAMK2N1 by grouped groups in different brain cell types, exemplified by microglia and
348 endothelial cells. **(G)** Heatmap showed the differential expressed genes in astrocytes of US
349 group compared to the sham group. **(H)** Bar chart of GO terms showed enriched pathways in
350 the US group compared to the sham group.
351




352

353 **Supplementary Figure 4. Gene manipulations on sham and ischemic stroke mice did not**
 354 **cause further damage after LIFUS treatment. (A)** Western blotting and **(B)** quantification
 355 of HMGB1, FGF2 normalized to actin in ipsilateral mouse brain of 6 different groups, (n = 6
 356 mice/group). **(C)** mNSS, **(D)** tail suspension, **(E)** grid walking and **(F)** rotarod test showed
 357 that neurobehavioral outcomes of different groups, (n = 6 mice/group). **(G)** Western blotting
 358 and **(H)** quantification of CAMK2N1, p-CAMK2 normalized to actin in ipsilateral mouse
 359 brain of 6 different groups, (n = 4 mice/group). **(I)** mNSS, **(J)** tail suspension, **(K)** grid
 360 walking, and **(L)** rotarod test showed the neurobehavioral outcomes of different groups, (n =
 361 6 mice/group). Data are mean \pm SD.

362

363



364

365 **Supplementary Figure 5. Fiber photometry records showed calcium waveforms of one**
 366 **representative mouse in the eight groups. (A) and (B) Original waveform was excited by**
 367 **470 nm (green) and 410nm (blue) were detected in striatum perifocal region in 8 different**
 368 **groups at day 7 and 13 after MCAO. (C) and (D) Original waveform was detected in left hind**
 369 **leg of 8 different groups at day 7 and 13 after MCAO.**
 370

Fig. 3D







Fig. 5D



Supplementary Fig. 4A



Supplementary Fig. 4G



371

372 **Supplementary Figure 6. Raw data of western blot.**

373

374 **Supplementary Tables**375 **Table S1 Ultrasonic parameters design.**

376

I _{SPTA} (mW/cm ²)	f (kHz)	PRF (kHz)	SD (ms)	DC (%)	Pr (Mpa)
22	500	1	300	50	0.117
101	500	1	300	50	0.250
201	500	1	300	50	0.352

377

378

379 **Table S2 Ultrasonic parameters combinations.**

380

ISPTA (mW/cm ²)	Stimulation time (min)	Interval (d)	Total time (d)
22/101/201	1	0	7
	1	1	5
	1	2	3
	3	0	7
	3	1	5
	3	2	3
	5	0	7
	5	1	5
	5	2	3

381

382

383 **Table S3 Ultrasonic parameters setting for further examination.**

384

I _{SPTA} (mW/cm ²)	Group	Stimulation time (min)	Interval (d)	Total time (d)
101	US1	3	1	4
101	US2	5	1	4
101	US3	10	1	4

385

386

387 **Table S4 Antibodies used in western blots.**

388

Antibody	Host	Catalogue Number	Vendor	Concentration
Hmgb1	Rabbit	10829-1-AP	Proteintech	1:1000
VEGFA	Rabbit	19003-1-AP	Proteintech	1:1000
FGF2	Mouse	05-118	Millipore	1:1000
CAMK2N1	Rabbit	PA5-23740	Thermo Fisher	1:1000
p-CaMKII	Mouse	sc-32289	Santa Cruz	1:500
BDNF	Mouse	sc-65514	Santa Cruz	1:1000
Synapsin I	Rabbit	AB1543	Millipore	1:1000
Homer1	Rabbit	ab184955	Abcam	Abcam
Glutamate receptor 1	Rabbit	ab31232	Abcam	1:1000
VGLUT1	Mouse	MAB5502	Millipore	1:1000
VGLUT2	Mouse	MAB5504	Millipore	1:1000
VGAT	Rabbit	AB5062P	Millipore	1:1000
Gephyrin	Rabbit	ab177154	Abcam	1:1000
b-actin	Mouse	66009	Proteintech	1:2000

389